Inhibition of TGFβ signaling and its implications in anticancer treatments

Inhibition of TGFβ signaling and its implications in anticancer treatments

The transforming growth factor-β (TGFβ) is a potent regulator of tumorigenesis. In cancer, two distinctive behaviors of TGFβ have been reported as a tumor suppressor at early stage of the disease, and as a tumor promoter at later stages. The past decades, the dualistic role of TGFβ has garnered a lo...

Full description

Saved in:
Bibliographic Details
Published in:Experimental Oncology
Date:2012
Main Authors: Calone, I., Souchelnytskyi, S.
Format: Article
Language:English
Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2012
Subjects:
Reviews
Online Access:https://nasplib.isofts.kiev.ua/handle/123456789/138683
Tags: Add Tag
No Tags, Be the first to tag this record!
Journal Title:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Cite this:Inhibition of TGFβ signaling and its implications in anticancer treatments / I. Calone, S. Souchelnytskyi // Experimental Oncology. — 2012. — Т. 34, № 1. — С. 9-16. — Бібліогр.: 95 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-138683
record_format dspace
spelling Calone, I.
Souchelnytskyi, S.
2018-06-19T11:37:07Z
2018-06-19T11:37:07Z
2012
Inhibition of TGFβ signaling and its implications in anticancer treatments / I. Calone, S. Souchelnytskyi // Experimental Oncology. — 2012. — Т. 34, № 1. — С. 9-16. — Бібліогр.: 95 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/138683
The transforming growth factor-β (TGFβ) is a potent regulator of tumorigenesis. In cancer, two distinctive behaviors of TGFβ have been reported as a tumor suppressor at early stage of the disease, and as a tumor promoter at later stages. The past decades, the dualistic role of TGFβ has garnered a lot of attention. As a result, cancer researchers’ has been tasked to elucidate how TGFβ signaling may lead to metastatic dissemination, how to tackle carcinogenesis and which therapeutic strategies should be adopted. Consequently, TGFβ signaling pathways have been considered as appropriate targets for cancer therapy. The TGFβ therapeutic strategies have emerged at three levels: ligand, ligand-receptor interaction and intracellular signaling level. Promising inhibitors of TGFβ signaling have entered clinical trials and shown encouraging results. Here we review the three strategies of TGFβ signa­ling inhibition and theirs applications in treatment of cancer.
Projects in the Souchelnytskyi group are supported by the Karolinska Biomics Center, the Karolinska Institute, the Swedish Research Council, the Swedish Institute, the Swedish Cancer Foundation, the EuroCanPlatform initiative, the King Gustav V Jubilee Fund, and the Ludwig institute for Cancer Research to S.S.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Reviews
Inhibition of TGFβ signaling and its implications in anticancer treatments
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Inhibition of TGFβ signaling and its implications in anticancer treatments
spellingShingle Inhibition of TGFβ signaling and its implications in anticancer treatments
Calone, I.
Souchelnytskyi, S.
Reviews
title_short Inhibition of TGFβ signaling and its implications in anticancer treatments
title_full Inhibition of TGFβ signaling and its implications in anticancer treatments
title_fullStr Inhibition of TGFβ signaling and its implications in anticancer treatments
title_full_unstemmed Inhibition of TGFβ signaling and its implications in anticancer treatments
title_sort inhibition of tgfβ signaling and its implications in anticancer treatments
author Calone, I.
Souchelnytskyi, S.
author_facet Calone, I.
Souchelnytskyi, S.
topic Reviews
topic_facet Reviews
publishDate 2012
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description The transforming growth factor-β (TGFβ) is a potent regulator of tumorigenesis. In cancer, two distinctive behaviors of TGFβ have been reported as a tumor suppressor at early stage of the disease, and as a tumor promoter at later stages. The past decades, the dualistic role of TGFβ has garnered a lot of attention. As a result, cancer researchers’ has been tasked to elucidate how TGFβ signaling may lead to metastatic dissemination, how to tackle carcinogenesis and which therapeutic strategies should be adopted. Consequently, TGFβ signaling pathways have been considered as appropriate targets for cancer therapy. The TGFβ therapeutic strategies have emerged at three levels: ligand, ligand-receptor interaction and intracellular signaling level. Promising inhibitors of TGFβ signaling have entered clinical trials and shown encouraging results. Here we review the three strategies of TGFβ signa­ling inhibition and theirs applications in treatment of cancer.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/138683
citation_txt Inhibition of TGFβ signaling and its implications in anticancer treatments / I. Calone, S. Souchelnytskyi // Experimental Oncology. — 2012. — Т. 34, № 1. — С. 9-16. — Бібліогр.: 95 назв. — англ.
work_keys_str_mv AT calonei inhibitionoftgfβsignalinganditsimplicationsinanticancertreatments
AT souchelnytskyis inhibitionoftgfβsignalinganditsimplicationsinanticancertreatments
first_indexed 2025-12-07T19:26:13Z
last_indexed 2025-12-07T19:26:13Z
_version_ 1850878799210610688

Similar Items